A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
evogliptin 5mg
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring DA-1229, evogliptin, DPP-IV inhibitor, Suganon, DPP-4 inhibitor
Eligibility Criteria
Inclusion Criteria:
- Subjects with 6.5%≤HbA1c≤10.0% at screening
- Subjects untreated with oral hypoglycemic agents within 6 weeks prior to screening
- Subjects with 6.5%≤HbA1c≤10.0% at Visit 2
- Subjects with 20kg/m2≤BMI≤40kg/m2 at screening
Exclusion Criteria:
- Subjects with fasting plasma glucose≥270mg/dL at screening
- Patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus
- Subjects with history of myocardial infarction, cerebral infarction within 6 months prior to screening
- Subjects with ALT and AST 2.5 times or higher than upper normal range
Sites / Locations
- Kangdong Sacred Heart Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
evogliptin 5mg
placebo
Arm Description
evogliptin 5mg QD
Placebo QD
Outcomes
Primary Outcome Measures
HbA1c
unit: %
Secondary Outcome Measures
fasting plasma glucose
unit: mg/dL
HbA1c response rate
unit: %
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02946541
Brief Title
A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin
Official Title
A Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Evogliptin After Oral Administration in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Diet and Exercise
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
July 2013 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
April 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dong-A ST Co., Ltd.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of evogliptin after oral administration in patients with type 2 diabetes who have inadequate glycemic control on diet and exercise.
Detailed Description
Evogliptin 5mg Group: Administration with Evogliptin 5mg for 0-52 weeks.
Placebo Group: Administration with Placebo for 0-24 weeks, and with Evogliptin 5mg for 24-52 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
DA-1229, evogliptin, DPP-IV inhibitor, Suganon, DPP-4 inhibitor
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
160 (Actual)
8. Arms, Groups, and Interventions
Arm Title
evogliptin 5mg
Arm Type
Experimental
Arm Description
evogliptin 5mg QD
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Placebo QD
Intervention Type
Drug
Intervention Name(s)
evogliptin 5mg
Other Intervention Name(s)
DA-1229, Suganon
Intervention Description
evogliptin 5mg, QD
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo, QD
Primary Outcome Measure Information:
Title
HbA1c
Description
unit: %
Time Frame
Change from baseline at 24 weeks
Secondary Outcome Measure Information:
Title
fasting plasma glucose
Description
unit: mg/dL
Time Frame
Change from baseline at 24 weeks
Title
HbA1c response rate
Description
unit: %
Time Frame
Change from baseline at 24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects with 6.5%≤HbA1c≤10.0% at screening
Subjects untreated with oral hypoglycemic agents within 6 weeks prior to screening
Subjects with 6.5%≤HbA1c≤10.0% at Visit 2
Subjects with 20kg/m2≤BMI≤40kg/m2 at screening
Exclusion Criteria:
Subjects with fasting plasma glucose≥270mg/dL at screening
Patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus
Subjects with history of myocardial infarction, cerebral infarction within 6 months prior to screening
Subjects with ALT and AST 2.5 times or higher than upper normal range
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Doo Man Kim, M.D., Ph.D.
Organizational Affiliation
Kangdong Sacred Heart Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kangdong Sacred Heart Hospital
City
Seoul
ZIP/Postal Code
134-701
Country
Korea, Republic of
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin
We'll reach out to this number within 24 hrs